BREADFRUIT: BaRiatric Surgery AnD FRUctose Handeling In Obese subjecTs
Study Details
Study Description
Brief Summary
To investigate whether changes in fructose dietary intake can help to improve dietary fructose-induced insulin resistance and post bariatric weight loss in obese subjects of Caucasian descent
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In this Randomized controlled trial, males and premenopausal women, scheduled for RYGB bariatric surgery at Spaarne Gasthuis of Caucasian Dutch descent, age ≥18 years will be put on either their high fructose diet (>100 gram fructose / day) versus a low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) 4 weeks before bariatric surgery. For both groups, an oral (13-C labeled) fructose challenge will be performed at baseline as well as 4 weeks after start of the diet (in the week of the surgery).
Outcome measures: Primary endpoints are changes in oral fructose induced glucose and insulin postprandial plasma excursions (measured by a fructose tolerance test with 120mg 13C6-labeled fructose in relation to long term glucose handling (HOMA and Freestyle Libre) at baseline and after 4 weeks (in the week of surgery) after both diets. Secondary endpoints are changes in histology and RNA seq gene expression in liver, adipose and jejunum tissue harvested with biopsy during bariatric surgery and changes in fecal gut microbiota composition, 24h feces and urine for fructose content and (postprandial) plasma metabolites including endogenous ethanol at both timepoints. Of note, dietary intake including fructose content will be monitored by an experienced dietician from Spaarne Gasthuis. Finally, to study relations with (long term) weight loss up to 1 year after surgery related to dietary intake, the last time points at 6 and 12 months after surgery (during regular clinical outpatient visits) will be used as an exploratory endpoint to gain more insight into the relationship between gut microbiota, (pre surgery) dietary fructose intake and weight loss after bariatric surgery.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: high fructose high fructose (>100 gram fructose / day) for 4 weeks |
Dietary Supplement: fructose
oral ingestion of fructose vs dextrose
Other Names:
|
| Other: low fructose low fructose diet (<30 gram fructose intake per day isocaloric correction with dextrose) for 4 weeks |
Dietary Supplement: fructose
oral ingestion of fructose vs dextrose
Other Names:
|
Outcome Measures
Primary Outcome Measures
- oral fructose handling [4 weeks]
to correlate changes in oral fructose excursions (measured by AUC of fructose tolerance test enriched with 13C6-labeled fructose with glucose excursions (MAGE by Freestyle Libre)
Secondary Outcome Measures
- fructose changes in visceral organs [4 weeks up to one year]
to correlate with changes in histology and RNA seq gene expression in liver, adipose and jejunum tissue harvested with biopsy during bariatric surgery
- gutmicrobiota [4 weeks up to one year]
to correlate with changes in fecal gut microbiota composition
- metabolites [4 weeks up to one year]
to correlate with (postprandial) plasma metabolites including endogenous ethanol
- weight [4 weeks up to one year]
to correlate with with (long term) weight loss at 6 and 12 months after surgery
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Scheduled for a RYGB gastric bypass*
-
Men and premenopausal women > 18 years of age
-
Caucasian descent
-
Ability to provide written informed consent
- All subjects on the waiting list meet the criteria for bariatric surgery, that is:
-
BMI > 40 kg/m2 OR >35 kg/m2 with obesity related co-morbidity
-
Reasonable supervised attempts to lose weight
Exclusion Criteria:
-
Unstable metabolic condition defined as;
-
Diabetes with poor glycemic control (HbA1c > 8.5%);
-
Use of an antidiabetic or anti-obesity drug;
-
Malabsorptive or restrictive bariatric (weight loss) surgery in history
-
Evidence for a form of liver disease (except for NAFLD without cirrhosis)
-
Known genetic basis for insulin resistance or glucose intolerance
-
Use of certain drugs known to produce hepatic steatosis in the previous 6 months (such as oral corticosteroids, high-dose estrogens, methotrexate, tetracycline, amiodarone)
-
Malabsorptive disease orders (celiac disease, inflammatory bowel disease)
-
Use of certain drugs that may injure the lining of the intestine in the previous months (colchicine, cholestyramine)
-
Excessive alcohol intake (≥5 IU per day or ≥ 14 IU per week)
-
Recent use of antibiotics (≤ 3 months before surgery)
-
Hemostasis disorders or current treatment with anticoagulants Any primary lipid disorder
-
Unable to maintain diet intervention, or unable to reliably rapport diet
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Amsterdam UMC location AMC | Amsterdam | Netherlands |
Sponsors and Collaborators
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2022.0595 - NL8236601822